Fonar Corp (DE:FOAA)
FRANKFURT:FOAA
FOAA Stock Chart & Stats
€13.20
-€0.30(-2.03%)
At close: 4:00 PM EST
€13.20
-€0.30(-2.03%)
Day’s Range― - ―
52-Week Range€11.90 - €16.30
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€104.00M
Enterprise Value€103.09M
Total Cash (Recent Filing)€53.77M
Total Debt (Recent Filing)€38.83M
Price to Earnings (P/E)17.6
Beta0.34
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.01
Shares Outstanding6,173,008
10 Day Avg. Volume7
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-0.59
Price to Book (P/B)0.55
Price to Sales (P/S)0.91
P/FCF Ratio12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageA low debt-to-equity (~0.22) and a sizable equity base materially reduce financial risk and preserve borrowing capacity. Over the next 2–6 months this supports capital allocation flexibility, resilience through reimbursement cycles, and room to fund R&D or facility investments without high leverage stress.
Integrated Business Model: Equipment + ServicesOwning both MRI product development and affiliated imaging operations creates diversified, potentially recurring revenue streams. Equipment sales provide product margin and install-network leverage while services offer utilization-driven cash flow and referral advantages that support long-term revenue stability.
Approved Going-Private TransactionThe near-term completion of a going-private transaction can remove public-market short-termism and reporting burdens, enabling management to execute multi-year product and service initiatives. This structural change can allow deeper reinvestment, operational restructuring, or long-horizon R&D investments without quarterly pressure.
Bears Say
Compressed ProfitabilityMargins have materially contracted from historical ranges (EBIT and net materially lower), reducing internal cash generation and the company's ability to fund growth or absorb reimbursement pressure. Sustained margin compression signals operational or pricing headwinds that could persist absent structural fixes.
Weaker Cash ConversionDeclining operating and free cash flow, with FCF covering only ~59% of net income, weakens the ability to self-fund capex, service growth investments or absorb cyclical downturns. Over months this raises dependence on external financing or parent support for major spending.
Stagnant / Weak Revenue MomentumFlat to negative top-line growth limits operating leverage and makes margin recovery harder. With services tied to scan volumes and equipment sales lumpy, persistent revenue stagnation constrains scale benefits, reduces bargaining power with payors, and heightens reliance on cost cuts or restructuring to lift profits.
Fonar News
FOAA FAQ
What was Fonar Corp’s price range in the past 12 months?
Fonar Corp lowest stock price was €11.90 and its highest was €16.30 in the past 12 months.
What is Fonar Corp’s market cap?
Fonar Corp’s market cap is €104.00M.
When is Fonar Corp’s upcoming earnings report date?
Fonar Corp’s upcoming earnings report date is Sep 29, 2026 which is in 112 days.
How were Fonar Corp’s earnings last quarter?
Fonar Corp released its earnings results on May 11, 2026. The company reported €0.21 earnings per share for the quarter, beating the consensus estimate of N/A by €0.21.
Is Fonar Corp overvalued?
According to Wall Street analysts Fonar Corp’s price is currently Overvalued.
Does Fonar Corp pay dividends?
Fonar Corp does not currently pay dividends.
What is Fonar Corp’s EPS estimate?
Fonar Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fonar Corp have?
Fonar Corp has 6,173,008 shares outstanding.
What happened to Fonar Corp’s price movement after its last earnings report?
Fonar Corp reported an EPS of €0.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fonar Corp?
Currently, no hedge funds are holding shares in DE:FOAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fonar Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth €9.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.84%
12-Months-Change
Fundamentals
Return on Equity
3.81%
Trailing 12-Months
Asset Growth
2.00%
Trailing 12-Months
Company Description
Fonar Corp
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.
Technical Analysis
Xtant Medical Holdings
―
Varex Imaging
―
Viemed Healthcare
―
Nano-X Imaging
―
Cytek Biosciences
―
Options Prices
Currently, No data available
---